Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of VM-1500A-LAI in Healthy Volunteers
NCT03706911Phase 1Completed
- Sponsor
- Viriom Inc
- Start
- Jan 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of depulfavirine long-acting injectable in human immunodeficiency virus type 1 infection (HIV-1) (5 arms), sponsored by Viriom Inc. Primary endpoints: Incidence of Adverse Events and Serious Adverse Events at 8 weeks and Concentration of VM1500A in plasma and RBCs at 8 weeks. Started Jan 2019; status: completed.
02
Drugs
depulfavirine long-acting injectable
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03706911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03706911.